Aiforia vs Mindpeak (2026)
Both sell CE-IVD pathology AI in Europe that is research use only in the United States, so the choice turns on scope and terms. Aiforia's Clinical Suites cover breast, lung, prostate, gastric and colon cancer on its own cloud platform with a worklist and viewer, and Aiforia Create lets laboratories build their own models. Mindpeak lists 11 CE-IVD biomarker products, including breast HER2, ER, PR and Ki-67 and lung PD-L1, reported IVDR certification in September 2026, and distributes through PathAI's AISight as well as its own hosted service.
- You want to build your own models as well as run marked ones, with Aiforia Create.
- Your security review asks for named certifications: Aiforia names ISO 27001, SOC 2 Type II and ISO 13485, and says its HIPAA Security Rule controls were independently audited.
- You want tumor detection and grading across five cancers on one platform.
- Biomarker scoring on immunohistochemistry is your main need.
- You already run PathAI's AISight, which distributes Mindpeak's algorithms.
- Multiplex immunofluorescence quantification matters to your research.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aiforia and Mindpeak are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Aiforia | Mindpeak |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2013 | 2018 |
| Headquarters | Helsinki, Finland | Hamburg, Germany |
| Website | aiforia.com | mindpeak.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Finnish deep learning pathology company, listed in Helsinki, selling cloud based image analysis for clinical diagnostics and preclinical research. Its Aiforia Clinical Suites cover breast, lung, prostate, gastric and colon cancer on a platform with a worklist, viewer and case reporting; each clinical model is CE-IVD marked for diagnostic use in the EU and EEA under the IVDR, or research use only, and all are research use only in the United States.
Source: AI Health Index, September 2026
Hamburg based computational pathology company, with a US entity in Cambridge, Massachusetts, focused on biomarker quantification from H&E, immunohistochemistry and multiplex immunofluorescence images. It lists 11 CE-IVD products, covering breast HER2, ER, PR and Ki-67 and lung PD-L1, reported IVDR certification in September 2026, and states that its other products are research use only; it has no FDA clearance.
Source: AI Health Index, September 2026
Questions buyers ask
How do Aiforia and Mindpeak work with the EHR?
The clinical solutions page says Aiforia integrates into existing laboratory systems, with publicly available API specifications, and that customers choose among deployment options. A sales and marketing partnership with Siemens Healthineers extends distribution.
With Mindpeak, the algorithm reaches the pathologist through someone else's product. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Aiforia and Mindpeak handle patient data?
In Aiforia's case, the company names ISO 27001 and SOC 2 Type II, states that its HIPAA Security Rule controls were independently tested, and says customers can choose between deployment options.
For Mindpeak, the customer must warrant that it owns the necessary rights and has obtained all applicable consents. The upload policy page is marked noindex, so search engines do not surface it. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Aiforia and Mindpeak?
Academic work using the Aiforia Create platform appears in Nature and in Mayo Clinic and MSKCC studies, though most of that is research use rather than validation of the clinical suites.
In Mindpeak's case, a study by Abele and colleagues assessed the Breast Ki-67 and ER/PR products for quantifying Ki-67, ER, and PR, finding reliability across a wide range of image variance and pathologist confirmation, and concluding the tools can improve interobserver agreement in real world clinical settings. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Aiforia and Mindpeak leave to the clinician?
For Aiforia, the marketed benefit is time saved and consistency, not autonomous sign out, and the CE-IVD models are sold as diagnostic aids.
Mindpeak ships both region of interest products, where the pathologist selects the area analyzed, and whole slide analysis. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Mindpeak's general terms grant it a perpetual, sublicensable right to use analyzed images, including to retrain its AI; read them before sending clinical images. Neither is FDA cleared. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.